Key Highlights
- Bruker's $0.05 quarterly common Dividend trades ex-date September 21, 2026, payable October 7, yielding approximately 0.32%, unchanged from prior quarters.
- Second-quarter Revenue was $838.5 million, up 5.2% year over year, though a $134.9 million Goodwill Impairment drove a GAAP diluted loss per share of $(0.41).
- Non-GAAP diluted EPS was $0.49 for the quarter, with the company updating full-year guidance to $2.10-$2.15 non-GAAP EPS, up 15% to 17% year over year.
- Bruker Scientific Instruments bookings increased 10% organically year over year, with book-to-bill exceeding 1.0 times.
Bruker Corporation's (NASDAQ:BRKR) $0.05 quarterly common dividend yields approximately 0.32%, a rate the board approved on August 14, 2026, unchanged from the prior quarter's declaration despite a GAAP net loss driven by a goodwill impairment charge. The dividend is a fixed per-share amount not directly tied to a stated Payout Ratio against non-GAAP or GAAP earnings, and it continued at the same rate through a quarter in which reported GAAP results and non-GAAP results diverged sharply.
Dividend Program and Shareholder Returns
Bruker's board declared a quarterly Cash Dividend of $0.05 per share on its common stock on August 14, 2026, payable October 7 to shareholders of record September 21. The rate equals $0.20 annualized and has remained unchanged across multiple recent quarters. The company separately pays a quarterly cash dividend on its 6.375% Mandatory Convertible Preferred Stock, Series A, which is a distinct, contractually fixed obligation and not part of the common stock payout.
About the Company
Bruker is a supplier of high-performance scientific instruments and analytical diagnostic solutions, operating through Bruker Scientific Instruments and Bruker BioSciences segments serving life sciences, diagnostics, applied markets and preclinical imaging customers across pharmaceutical, biotechnology, academic and industrial settings worldwide.
Financial Performance Behind the Payout
Bruker reported second-quarter revenue of $838.5 million, up 5.2% year over year, or 2.8% organically. GAAP diluted loss per share was $(0.41), reflecting a $134.9 million goodwill impairment charge. Non-GAAP diluted EPS was $0.49. After interest, taxes and $10.9 million of preferred dividends, net loss attributable to common shareholders was $62.9 million. Bruker Scientific Instruments bookings increased 10% organically year over year, with book-to-bill exceeding 1.0 times. The company updated full-year 2026 guidance to revenue of $3.54 billion to $3.57 billion, up 3% to 4%, and non-GAAP EPS of $2.10 to $2.15, up 15% to 17%.
A Fixed Per-Share Rate Through a GAAP-Non-GAAP Divergence
Bruker's continuation of the $0.05 common dividend through a quarter with a GAAP net loss reflects the fact that the goodwill impairment is a non-cash accounting charge rather than a change in the company's underlying cash generation, a distinction the non-GAAP diluted EPS of $0.49 is intended to isolate. The 10% organic bookings growth in the Bruker Scientific Instruments segment, with book-to-bill exceeding 1.0 times, indicates order Volume outpaced quarterly revenue recognition, a forward indicator separate from either the GAAP or non-GAAP Earnings figures for the quarter itself. Full-year guidance was updated only for currency and tax changes rather than for operational factors, according to the company's own characterization of the update.
Outlook
Metrics relevant to the common dividend's continuation include non-GAAP EPS trajectory toward the $2.10-$2.15 full-year guidance range, Bruker Scientific Instruments bookings and book-to-bill trends, and the size of future impairment or one-time charges relative to non-cash accounting adjustments. Organic revenue growth by segment and Margin performance excluding the goodwill impairment remain relevant to the underlying trend.

_09_30_2026_02_08_20_566201.jpg)




Please wait processing your request...